Outlook Therapeutics, Inc. (OTLK): what it filed
Regulatory filings for Outlook Therapeutics, Inc. (OTLK), each one linked back to the document it was parsed from, and each score stating the inputs it was built from.
Streams covered here: 5%+ stake filing (13d/g), insider buying cluster.
Recent filings
2026-08-19 - 5%+ stake filing (13D/G) - score 50/100
holder: CVI Investments, Inc. · intent: New passive 5%+ stake (13G) · is amendment: Original filing
2026-08-14 - 5%+ stake filing (13D/G) - score 75/100
holder: GMS Ventures & Investments · intent: Activist stake change (13D/A) - position or intent updated - 16.4% of class · is amendment: Amendment
2026-08-14 - Insider buying cluster - score 67/100
conviction: MODERATE · last buy: 2026-08-14 · num buys: 3 · total value usd: $2,499,999
Being straight about what this is
Not advice. This page reports what a public filing says and links to it. It draws no conclusion from that.
Some scores are built on incomplete inputs. Where a filing does not publish every term the formula uses, the record carries inputs_complete: false and the score is still shown. The gap is reported, not filled in with a guess.
Refreshed once a night, and some publishers are slower by nature: congressional trades weekly, institutional holdings quarterly.
Names come from the filing. Where a person is named, that name is a required disclosure field in the public document, and the link above goes to it.
DataSignals Lab publishes data and research. Informational only, not investment advice, not an offer or solicitation. Every figure links back to the official filing so you can verify it yourself.